Impact of the Presence and Quantity of Ductal Carcinoma in Situ Component on the Outcome of Invasive Breast Cancer

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2016 Jan 2

PMID 26722534

Citations 8

Authors

Carla Cedolini

Serena Bertozzi

Ambrogio P Londero

Luca Seriau

Michela Andretta

Diane Agakiza

Sandro Fongione

Alessandro Uzzau

Andrea Risaliti

Affiliations

Soon will be listed here.

Abstract

Introduction: The role of ductal carcinoma in situ (DCIS) component on the outcome of invasive breast cancer is not yet completely clear. Our study aims to assess the impact of the presence and quantity of DCIS component on the outcome of patients operated for invasive breast cancer.

Materials And Methods: We collected retrospective data about patients operated at their breast for invasive cancer between 2007 and 2012, focusing on the presence of DCIS component. Then, we divided patients into four groups based on the quantity of DCIS component as follows: not found (group A), minimal (group B, <25%), extensive (group C, 25-75%), and prevalent (group D, >75%). We further defined "extensive intraductal component" (EIC) groups C and D together.

Results: DCIS component was associated with young age, familial history of breast cancer and worse biological characteristics, including high grading, higher prevalence of Her2/Neu overexpression, hormone receptors negativity, comedo-like necrosis and multifocality/multicentricity. Despite the unfavorable prognostic factors, invasive cancers associated with EIC were frequently treated with radical surgery and resulted to have long disease-free survival and low local recurrence rate. In patients with DCIS component (groups B, C, and D) the extension of this component resulted indirectly correlated with local recurrence rate, tumor lymphovascular invasion, and lymphnode extracapsular invasion. The highest prevalence of local recurrences was found in group B, which tended to be less frequently treated with radical surgery than group D (P<0.05) and C (P=n.s.).

Conclusions: Different clinical and tumor features among invasive breast cancer with and without DCIS component indicate that they are distinct entities probably originating by different pathways that deserve to be studied. Furthermore, the controversial results about the management of cancer with minimal intraductal component require further studies in order to reduce local recurrence.

Citing Articles

Prognostic implications of ductal carcinoma components in -positive breast cancer: a retrospective cohort study.

Yoon K, Kim E, Shin H Ann Surg Treat Res. 2024; 107(6):327-335.

PMID: 39669383 PMC: 11634396. DOI: 10.4174/astr.2024.107.6.327.

Extensive intraductal component as a factor determining local recurrence of breast cancer: a systematic review and meta-analysis.

Polchai N, Thongvitokomarn S Gland Surg. 2023; 12(10):1336-1347.

PMID: 38021199 PMC: 10660179. DOI: 10.21037/gs-23-137.

Multitask deep learning on mammography to predict extensive intraductal component in invasive breast cancer.

Tsai H, Kao Y, Wang J, Tsai T, Chung W, Hsu J Eur Radiol. 2023; 34(4):2593-2604.

PMID: 37812297 DOI: 10.1007/s00330-023-10254-6.

Prognostic value of integrin αV expression and localization pattern in invasive breast carcinomas.

Cerqueira O, Botelho M, Fiore A, Osorio C, Tomasin R, Cafundo Morais M Neoplasia. 2022; 30:100803.

PMID: 35526305 PMC: 9092997. DOI: 10.1016/j.neo.2022.100803.

TFEB, SIRT1, CARM1, Beclin-1 expression and PITX2 methylation in breast cancer chemoresistance: a retrospective study.

Bertozzi S, Londero A, Viola L, Orsaria M, Bulfoni M, Marzinotto S BMC Cancer. 2021; 21(1):1118.

PMID: 34663249 PMC: 8524961. DOI: 10.1186/s12885-021-08844-y.

References

Ikeda D, Andersson I . Ductal carcinoma in situ: atypical mammographic appearances. Radiology. 1989; 172(3):661-6. DOI: 10.1148/radiology.172.3.2549563. View

Arnone P, Zurrida S, Viale G, Dellapasqua S, Montagna E, Arnaboldi P . The TNM classification of breast cancer: need for change. Updates Surg. 2010; 62(2):75-81. DOI: 10.1007/s13304-010-0014-y. View

Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L . European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document. Ann Oncol. 2007; 19(4):614-22. DOI: 10.1093/annonc/mdm481. View

Bernardi S, Bertozzi S, Londero A, Angione V, Petri R, Giacomuzzi F . Prevalence and risk factors of intraoperative identification failure of sentinel lymph nodes in patients affected by breast cancer. Nucl Med Commun. 2013; 34(7):664-73. DOI: 10.1097/MNM.0b013e328361cd84. View

Lopez-Garcia M, Geyer F, Lacroix-Triki M, Marchio C, Reis-Filho J . Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 2010; 57(2):171-92. DOI: 10.1111/j.1365-2559.2010.03568.x. View

Kang D, Jeon G, Yim H, Jung Y . Diagnosis of the intraductal component of invasive breast cancer: assessment with mammography and sonography. J Ultrasound Med. 2007; 26(11):1587-600. DOI: 10.7863/jum.2007.26.11.1587. View

Tazzite A, Jouhadi H, Saiss K, Benider A, Nadifi S . Relationship between family history of breast cancer and clinicopathological features in Moroccan patients. Ethiop J Health Sci. 2013; 23(2):150-7. PMC: 3742892. View

Yagata H, Harigaya K, Suzuki M, Nagashima T, Hashimoto H, Ishii G . Comedonecrosis is an unfavorable marker in node-negative invasive breast carcinoma. Pathol Int. 2003; 53(8):501-6. DOI: 10.1046/j.1440-1827.2003.01514.x. View

Patchefsky A, Schwartz G, Finkelstein S, Prestipino A, Sohn S, Singer J . Heterogeneity of intraductal carcinoma of the breast. Cancer. 1989; 63(4):731-41. DOI: 10.1002/1097-0142(19890215)63:4<731::aid-cncr2820630422>3.0.co;2-#. View

10.

Robson M, Rajan P, Rosen P, Gilewski T, Hirschaut Y, Pressman P . BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res. 1998; 58(9):1839-42. View

11.

Bernardi S, Bertozzi S, Londero A, Giacomuzzi F, Angione V, Dri C . Nine years of experience with the sentinel lymph node biopsy in a single Italian center: a retrospective analysis of 1,050 cases. World J Surg. 2012; 36(4):714-22. DOI: 10.1007/s00268-011-1420-0. View

12.

Yiu C, Loo W, Lam C, Chow L . Presence of extensive intraductal component in patients undergoing breast conservative surgery predicts presence of residual disease in subsequent completion mastectomy. Chin Med J (Engl). 2009; 122(8):900-5. View

13.

van la Parra R, Peer P, Ernst M, Bosscha K . Meta-analysis of predictive factors for non-sentinel lymph node metastases in breast cancer patients with a positive SLN. Eur J Surg Oncol. 2011; 37(4):290-9. DOI: 10.1016/j.ejso.2011.01.006. View

14.

Thike A, Iqbal J, Cheok P, Man-Kit Tse G, Tan P . Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor-product relationship. J Clin Pathol. 2013; 66(8):665-70. DOI: 10.1136/jclinpath-2012-201428. View

15.

Recht A, Connolly J, Schnitt S, Silver B, Rose M, Love S . The effect of young age on tumor recurrence in the treated breast after conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 1988; 14(1):3-10. DOI: 10.1016/0360-3016(88)90043-0. View

16.

LAGIOS M, WESTDAHL P, Margolin F, Rose M . Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer. 1982; 50(7):1309-14. DOI: 10.1002/1097-0142(19821001)50:7<1309::aid-cncr2820500716>3.0.co;2-#. View

17.

Kim J, Han W, Moon H, Park I, Ahn S, Kim J . Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor. Clin Breast Cancer. 2013; 13(5):385-91. DOI: 10.1016/j.clbc.2013.04.005. View

18.

Jacquemier J, Kurtz J, Amalric R, BRANDONE H, AYME Y, Spitalier J . An assessment of extensive intraductal component as a risk factor for local recurrence after breast-conserving therapy. Br J Cancer. 1990; 61(6):873-6. PMC: 1971685. DOI: 10.1038/bjc.1990.195. View

19.

Schwartz G, Patchefsky A, Finklestein S, Sohn S, Prestipino A, Feig S . Nonpalpable in situ ductal carcinoma of the breast. Predictors of multicentricity and microinvasion and implications for treatment. Arch Surg. 1989; 124(1):29-32. DOI: 10.1001/archsurg.1989.01410010035007. View

20.

van Dongen J, Fentiman I, Harris J, Holland R, Peterse J, Salvadori B . In-situ breast cancer: the EORTC consensus meeting. Lancet. 1989; 2(8653):25-7. DOI: 10.1016/s0140-6736(89)90263-8. View